

Curriculum Vitae

Personal Information

Name: Alberto Bongiovanni

Date of Birth: [hidden]

Place of Birth: [hidden]

Nationality: Italian

Phone: [hidden]

Institutional Email: alberto.bongiovanni@unicamillus.org

ORCID: 0000-0002-3845-4687

Education

- 2000: High School Diploma in Classical Studies (100/100).
- 2006: MD in Medicine and Surgery, Thesis on “Prognostic value of the extracellular domain of serum her2/neu in patients with early and metastatic breast cancer” (110/110 cum laude, distinction and award proposal “A. Rotolo”).
- 2007: License to practice as Medical Doctor and Surgeon (Italy).
- 2008–2012: Specialisation in Medical Oncology.
- 2018–2022: PhD in Experimental Oncology, Haematology and Clinical Pathology, University of Bologna. Thesis: “A randomized phase II trial of captem or folfiri as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)” (with honours).
- 2023–2024: Master’s Degree (2nd level) in Clinical Research and Medical Affairs, 240reBS.

Academic Titles

- 2008: Eligibility for admission to the School of Specialisation in Medical Oncology.
- 2012: Diploma of Specialisation in Medical Oncology.
- 2022: PhD in Oncology, Haematology and General Pathology, University of Bologna.
- 2023: National Scientific Qualification as Associate Professor (SSD 06/D3 Blood Diseases, Oncology and Rheumatology – valid until 2033).
- 2023: Eligibility for Associate Professorship, University of Ferrara.

Professional Experience

- Since Sept 2025: Researcher at UniCamillus – International Medical University in Rome.
- 2012–2023: Consultant at IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST “Dino Amadori”). Initially focused on thoracic oncology, later at the Centre for Osteoncology and Rare Tumours (CDO-TR). Duties included outpatient and day-hospital clinical care, specialist consultancy, clinical research in rare cancers and bone metastases, and participation as Principal Investigator and Co-Investigator in numerous phase I–IV clinical trials (both industry-sponsored and investigator-initiated).
- 2012: Multidisciplinary Team Physician, SISIFO Association, ASP Trapani.
- 2007–2012: General Practitioner substitute in ASP Palermo and Trapani.

Teaching Activities

- Lecturer, University of Ferrara (2017), Master’s in Health and Wellbeing Prevention.
- Tutor for oncology residents (2021, University of Ancona).
- Thesis co-supervisor, Specialisation in Oncology, University of Ancona (2021).
- Lecturer, University of Bologna, Master’s in Clinical Pharmacy 4.0 (2022).
- Invited speaker in multiple national and international workshops and congresses (2013–2023).

Research Activities

- 2020–2023: Clinical research coordinator and member of the core management team, Osteoncology and Rare Tumours, IRST Meldola.
- Principal Investigator of national multicentre studies (e.g., SENECA study, Banca Dati Nazionale Metastasi Ossee, DINAMICA project).
- Recipient of competitive research grants (e.g., AVATAR project, Italian Ministry of Health “Giovani Ricercatori”).
- Reviewer for >50 peer-reviewed journals including New England Journal of Medicine, BMC Cancer, Frontiers in Oncology, Scientific Reports.
- Associate/Section Editor roles in peer-reviewed journals (OncoTargets and Therapy, BMC Cancer, Frontiers in Oncology, Precision Cancer Medicine).
- Author of 96 peer-reviewed international publications (H-index 32, >2400 citations).

List of Paper Published in Peer Reviewed Journals

1. Meena AS, Bongiovanni A. Editorial: From bench to bedside in gastric cancer: diagnosis, prognosis, and treatment, volume II. *Front Med (Lausanne)*. 2025 Mar 11;12:1562989. IF= 3.1
2. Calabrese C, Miserochi G, De Vita A, Spadazzi C, Cocchi C, Vanni S, Gabellone S, Martinelli G, Ranallo N, Bongiovanni A, Liverani C. Lipids and adipocytes involvement in tumor progression with a focus on obesity and diet. *Obes Rev*. 2024 Dec;25(12):e13833. doi: 10.1111/obr.13833. IF=8.0
3. Severi S, Grassi I, Bongiovanni A, Nicolini S, Marini I, Arpa D, Ranallo N, Azzali I, Di Iorio V, Sarnelli A, Manuela M, Amadori E, Fabbri L, Bartolini D, Tosatto L, Di Meco F, Gurrieri L, Riva N, Calabro L, Matteucci F, Paganelli G, Sansovini M. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. *J Nucl Med*. 2024 Aug 14;jnumed.123.266956. doi: 10.2967/jnumed.123.266956. IF= 9.3
4. Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, Pusceddu S, Grana CM, Corssmit EPM, Bongiovanni A, De Filpo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. *Eur J Cancer*. 2024 Sep;208:114122. doi: 10.1016/j.ejca.2024.114122. IF 7.6
5. Bongiovanni A, Liverani C, Foca F, Bergamo F, Leo S, Pusceddu S, Gelsomino F, Brizzi MP, Di Meglio G, Spada F, Tamberi S, Lolli I, Cives M, Marconcini R, Pucci F, Berardi R, Antonuzzo L, Badalamenti G, Santini D, Recine F, Vanni S, Tebaldi M, Severi S, Rudnas B, Nanni O, Ranallo N, Crudi L, Calabrò L, Ibrahim T. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas. *Eur J Cancer*. 2024 Sep;208:114129. doi: 10.1016/j.ejca.2024.114129. IF 7.6
6. Recine F, Vanni S, Bongiovanni A, Fausti V, Mercatali L, Miserochi G, Liverani C, Pieri F, Casadei R, Cavaliere D, Falbo PT, Diano D, Ibrahim T, De Vita A. Clinical and translational implications of immunotherapy in sarcomas. *Front Immunol*. 2024 Jun 25;15:1378398. doi: 10.3389/fimmu.2024.1378398. IF 5.7
7. Panzuto F, Andrini E, Lamberti G, Pusceddu S, Rinzivillo M, Gelsomino F, Raimondi A, Bongiovanni A, Davì MV, Cives M, Brizzi MP, Persano I, Zatelli MC, Puliafito I, Tafuto S, Campana D. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort. *J Clin Med*. 2024 Apr 3;13(7):2074. doi:10.3390/jcm13072074. IF 3.0

8. Recine F, Bongiovanni A, Mercatali L, Fausti V, Ferraresi V, De Vita A. Editorial: The immune infiltrate as a paradigm model to study the biology and novel therapeutic approaches in sarcomas. *Front. Endocrinol (Lausanne)*. 2023 Dec 4;14:1334519. doi: 10.3389/fendo.2023.1334519. IF 3.9
9. Miserocchi G, Bassi M, De Luca G, Calpona S, De Rosa F, Bongiovanni A, Parisi E, Di Menna G, De Vita A, Liverani C, Spadazzi C, Cocchi C, Vanni S, Capelli L, Magnani M, Meccariello G, Vicini C, Campobassi A, Mercatali L, Ibrahim T. High-grade transformation of a polymorphous adenocarcinoma of the salivary gland: a case report and review of the literature. *Front Oncol*. 2023 Sep 18;13:1245043. doi: 10.3389/fonc.2023.1245043. IF 3.5
10. Lamberti G, Prinzi N, Bongiovanni A, Torniai M, Andrini E, Biase D, Malvi D, Mosca M, Berardi R, Ibrahim T, Pusceddu S, Campana D. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). *Diagnostics (Basel)*. 2023 Apr 29;13(9):1595. doi: 10.3390/diagnostics13091595. PMID: 37174986 IF =3.992
11. Fazio N, Gervaso L, Halfdanarson TR, Sonbol M, Eiring RA, Pusceddu S, Prinzi N, Lombardi Stocchetti B, Grozinsky-Glasberg S, Gross DJ, Walter T, Robelin P, Lombard-Bohas C, Frassoni S, Bagnardi V, Antonuzzo L, Sparano C, Massironi S, Gelsomino F, Bongiovanni A, Ranallo N, Tafuto S, Rossi M, Cives M, Rasul KI, Hamid H, Chirco A, Squadroni M, La Salvia A, Hernando J, Hofland J, Koumariou A, Boselli S, Tamayo D, Mazzon C, Rubino M, Spada F. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study. *Endocr Relat Cancer*. 2023 Mar 1:ERC-22-0395. doi: 10.1530/ERC-22-0395. Online ahead of print. PMID: 36930250 IF= 5.905
12. Fausti V, De Vita A, Vanni S, Ghini V, Gurrieri L, Riva N, Casadei R, Maraldi M, Ercolani G, Cavaliere D, Pacilio CA, Pieri F, Foca F, Bongiovanni A, Ranallo N, Calpona S, Frassinetti GL, Ibrahim T, Mercatali L. Systemic Inflammatory Indices in Second-Line Soft Tissue Sarcoma Patients: Focus on Lymphocyte/Monocyte Ratio and Trabectedin. *Cancers (Basel)*. 2023 Feb 8;15(4):1080. doi: 10.3390/cancers15041080. PMID: 36831421 IF=6.575
13. Liverani C, Spadazzi C, Ibrahim T, Pieri F, Foca F, Calabrese C, De Vita A, Miserocchi G, Cocchi C, Vanni S, Ercolani G, Cavaliere D, Ranallo N, Chiadini E, Prisinzano G, Severi S, Sansovini M, Martinelli G, Bongiovanni A, Mercatali L. HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors. *Front Endocrinol (Lausanne)*. 2023 Jan 20;13:1045038. doi: 10.3389/fendo.2022.1045038. eCollection 2022. PMID: 36743926 IF= 6.055
14. Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N, Matteucci F, Paganelli G, Severi S. 177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. *Cancers (Basel)*. 2022 Dec 7;14(24):6022. doi:10.3390/cancers14246022. PMID: 36551507 IF=6.575

15. Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, Panzuto F, Tomazic A, Bongiovanni A, Kaltsas G, Sauvanet A, Bertani E, Mazzaferro V, Caplin M, Armstrong T, Weickert MO, Ramage J, Segelov E, Butturini G, Staettner S, Cives M, Frilling A, Moulton CA, He J, Boesch F, Selberheer A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Holzer K, Wilson CH, Almeamar H, Vigia E, Muffatti F, Lucà M, Lania A, Ewald J, Kim H, Salvia R, Rinzivillo M, Smid A, Gardini A, Tsoli M, Hentic O, Colombo S, Citterio D, Toumpanakis C, Ramsey E, Randeve HS, Srirajaskanthan R, Croagh D, Regi P, Gasteiger S, Invernizzi P, Ridolfi C, Giovannini M, Jang JY, Bassi C, Falconi M. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. *Br J Surg.* 2022 Nov 22;109(12):1186-1190. doi:10.1093/bjs/znac267. PMID: 35986682 IF =11.782
16. Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez- Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study. *ESMO Open.* 2022 Oct;7(5):100562. doi: 10.1016/j.esmoop.2022.100562. Epub 2022 Aug 18. PMID: 35987165; PMCID: PMC9588873. IF=6.883
17. Bongiovanni A, Frassoldati A, Calabro' L. Immunotherapy in malignant pleural mesothelioma: a long story ended in success. *J Cancer Metastasis Treat* 2022;8:44. <http://dx.doi.org/10.20517/2394-4722.2022.78>
18. Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassinetti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. *Cancers (Basel).* 2022 Jun 30;14(13):3231. IF= 6.575
19. Vanni S, De Vita A, Gurrieri L, Fausti V, Miserocchi G, Spadazzi C, Liverani C, Cocchi C, Calabrese C, Bongiovanni A, Riva N, Mercatali L, Pieri F, Casadei R, Lucarelli E, Ibrahim T. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. *Ther Adv Med Oncol.* 2022 Jun 28;14:17588359221093973. IF= 5.485
20. Ranallo N, Bocchini M, Menis J, Pilotto S, Severi S, Liverani C, Bongiovanni A. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. *Expert Rev Anticancer Ther.* 2022 Jun;22(6):597-603. doi: 10.1080/14737140.2022.2071703. IF= 3.627
21. Bongiovanni A, Foca F, Oboldi D, Diano D, Bazzocchi A, Fabbri L, Mercatali L, Vanni S, Maltoni M, Bianchini D, Casadei C, Matteucci F, Nanni O, Rossi B, Sintuzzi E, Martoni ME,

Zavoiu V, Barone D, Altini M, Ibrahim T. 3-T magnetic resonance-guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. *Support Care Cancer*. 2022 Jul;30(7):5737-5745. doi: 10.1007/s00520-022-06990-y. IF= 3.359

22. De Vita A, Vanni S, Miserocchi G, Fausti V, Pieri F, Spadazzi C, Cocchi C, Liverani C, Calabrese C, Casadei R, Recine F, Gurrieri L, Bongiovanni A, Ibrahim T, Mercatali L. Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. *Biomedicines*. 2022 Feb 3;10(2):372. doi: 10.3390/biomedicines10020372. IF=4.757

23. Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregini E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. *JAMA Netw Open*. 2022 Feb 1;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290. IF =13.360

24. Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, Di Iorio V, Germanó L, Caroli P, Sarnelli A, Paganelli G, Severi S. Theragnostic in neuroendocrine tumors. *Q J Nucl Med Mol Imaging*. 2021 Dec 9. IF= 1.560

25. Bongiovanni A, Foca F, Menis J, Stucci SL, Artioli F, Guadalupi V, Forcignanò MR, Fantini M, Recine F, Mercatali L, Spadazzi C, Burgio MA, Fausti V, Miserocchi A, Ibrahim T. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio. *Front Immunol*. 2021 Nov 10;12:697298. IF= 8.787

26. Severi S, Bongiovanni A, Ferrara M, Nicolini S, Di Mauro F, Sansovini M, Lolli I, Tardelli E, Cittanti C, Di Iorio V, Mezzenga E, Scarpi E, Ibrahim T, Paganelli G, Zovato S. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. *ESMO Open*. 2021 Aug;6(4):100171. IF= 6.540

27. De Vita A, Vanni S, Fausti V, Cocchi C, Recine F, Miserocchi G, Liverani C, Spadazzi C, Bassi M, Gessaroli M, Campobassi A, De Luca G, Pieri F, Farnedi A, Franchini E, Ferrari A, Domizio C, Cavagna E, Gurrieri L, Bongiovanni A, Riva N, Calpona S, Di Menna G, Debonis SA, Ibrahim T, Mercatali L. Deciphering the Genomic Landscape and Pharmacological Profile of

Uncommon Entities of Adult Rhabdomyosarcomas. *Int J Mol Sci.* 2021 Oct 26;22(21):11564. IF= 6.208

28. De Vita A, Ferrari A, Miserocchi G, Vanni S, Domizio C, Fonzi E, Fausti V, Recine F, Bassi M, Campobassi A, Liverani C, Spadazzi C, Cocchi C, De Luca G, Pieri F, Gurrieri L, Di Menna G, Calpona S, Bongiovanni A, Martinelli G, Ibrahim T, Mercatali Identification of a novel RAB3IPHMGA2 fusion transcript in an adult head and neck rhabdomyosarcoma. *L.Oral Dis.* 2021 Sep 30. IF= 4.068

29. Liverani C, De Vita A, Spadazzi C, Miserocchi G, Cocchi C, Bongiovanni A, De Lucia A, La Manna F, Fabbri F, Tebaldi M, Amadori D, Tasciotti E, Martinelli G, Mercatali L, Ibrahim T Lineage-specific mechanisms and drivers of breast cancer chemoresistance revealed by 3D biomimetic culture. *Mol Oncol.* 2021 Jun 10. IF=7.449

30. Bongiovanni A, Maiorano BA, Azzali I, Liverani C, Bocchini M, Fausti V, Di Menna G, Grassi I, Sansovini M, Riva N, Ibrahim T Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. *.Pharmaceuticals (Basel).* 2021 May 17;14(5):476. IF= 5.215

31. Debonis SA, Bongiovanni A, Pieri F, Fausti V, De Vita A, Riva N, Gurrieri L, Vanni S, Diano D, Mercatali L, Ibrahim T. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations. *Medicine (Baltimore).* 2021 May 21;100(20):e25972. IF =1.817

32. De Vita A, Recine F, Miserocchi G, Pieri F, Spadazzi C, Cocchi C, Vanni S, Liverani C, Farnedi A, Fabbri F, Fausti V, Casadei R, Brandolini F, Ercolani G, Cavaliere D, Bongiovanni A, Riva N, Gurrieri L, Di Menna G, Calpona S, Debonis SA, Mercatali L, Ibrahim T The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models. *J Exp Clin Cancer Res.* 2021 May 11;40(1):165. IF=12.658

33. Capdevila J, Fazio N, Lopez C, Teulé A, Valle JW, Tafuto S, Custodio A, Reed N, Raderer M, Grande E, Garcia-Carbonero R, Jimenez-Fonseca P, Hernando J, Bongiovanni A, Spada F, Alonso V, Antonuzzo L, Spallanzani A, Berruti A, La Casta A, Sevilla I, Kump P, Giuffrida D, Merino X, Trejo L, Gajate P, Matos I, Lamarca A, Ibrahim T Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). *J Clin Oncol.* 2021 Jul 10;39(20):2304-2312 IF= 50.739

34. Lilli C, Biggeri A, Zingaretti C, Vertogen B, Frassinetti V, Vespignani R, Grossi V, Florescu C, Matteucci L, Pazzi C, Bongiovanni A, Limarzi F, Fausti V, Bertoni L, Donati C, Galardi F, Gentili N, Mazza F, Martinelli G, Nanni O Is it possible to conduct clinical trials during a pandemic? The example of a trial of hydroxychloroquine. *.Epidemiol Prev.* 2021 Jan-Apr;45(1- 2):28-36. IF= 1.996

35. Miserocchi G, Cocchi C, De Vita A, Liverani C, Spadazzi C, Calpona S, Di Menna G, Bassi M, Meccariello G, De Luca G, Campobassi A, Maddalena Tumedei M, Bongiovanni A, Fausti V, Cotelli F, Ibrahim T, Mercatali L. Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas. *Cancer Biol Med*. 2021 Mar 27;j.issn.2095-3941.2020.0482.IF=5.347
36. De Vita A, Liverani C, Molinaro R, Martinez JO, Hartman KA, Spadazzi C, Miserocchi G, Taraballi F, Evangelopoulos M, Pieri F, Bongiovanni A, Mercatali L, Tasciotti E, Ibrahim T. Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer. *Sci Rep*. 2021 Mar 3;11(1):5107. IF=4.997
37. Bongiovanni A, Foca F, Fantini M, Forcignanò MR, Artioli F, Berardi R, Campadelli E, Procopio G, Silvestris F, Riva N, Gurrieri L, Debonis SA, Di Menna G, Fausti V, Recine F, Vespignani R, Ibrahim T. First prospective data on breast cancer patients from the multicentre italian bone metastasis database. *Sci Rep*. 2021 Feb 22;11(1):4329. IF=4.997
38. Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli Combined use of ¹⁷⁷LuDOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastroentero-pancreatic neuroendocrine tumors. *G.Eur J Nucl Med Mol Imaging*. 2021 Feb 18. IF=10.057
39. Bongiovanni A, Vagheggini A, Fausti V, Mercatali L, Calpona S, Di Menna G, Miserocchi G, Ibrahim T. Induction chemotherapy plus concomitant chemoradiotherapy in nasopharyngeal carcinoma: An updated network meta-analysis. *Crit Rev Oncol Hematol*. 2021 Feb 11;160:103244. IF=6.625
40. Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. *Endocr Pathol*. 2021 Jan 6. IF=4.056
41. Spadazzi C, Mercatali L, Esposito M, Wei Y, Liverani C, De Vita A, Miserocchi G, Carretta E, Zanoni M, Cocchi C, Bongiovanni A, Recine F, Kang Y, Ibrahim T. Trefoil factor-1 upregulation in estrogen receptor positive breast cancer correlates with an increased risk of bone metastasis. *Bone*. 2021 Mar;144:115775. IF = 4.626
42. Bongiovanni A, Liverani C, Foca F, Fausti V, Di Menna G, Mercatali L, De Vita A, Riva N, Calpona S, Miserocchi G, Spadazzi C, Cocchi C, Ibrahim T. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: a "Real World" data analysis. *Neuroendocrinology*. 2020 Nov 20. IF= 5.135
43. De Vita A, Bongiovanni A, Blay JY, Ibrahim T. Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective. *Front Oncol*. 2020 Oct 29;10:593785. IF 5.738

44. Cafaro A, Bongiovanni A, Di Iorio V, Oboldi D, Masini C, Ibrahim T. Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. *Front Oncol.* 2020 Aug 18;10:1478. IF 5.738
45. Giani C, Valerio L, Bongiovanni A, Durante C, Grani G, Ibrahim T, Mariotti S, Massa M, Pani F, Pellegriti G, Porcelli T, Salvatore D, Tavarelli M, Torlontano M, Locati L, Molinaro E, Elisei R Safety and quality of life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer. *Thyroid.* 2020 Sep 10. IF 6.506
46. Bongiovanni A, Liverani C, Pusceddu S, et al. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. *BMJ Open.* 2020;10(7):e034393. IF 3.007
47. Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. *Eur J Nucl Med Mol Imaging.* 2021 Jan;48(1):152-160. IF= 10.057
48. Bongiovanni A, Mercatali L, Fausti V, Ibrahim T. Comment on 'Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey' by Alice Indini et al. *Eur J Cancer.* 2020;134:3-5. doi:10.1016/j.ejca.2020.04.047 IF:10.002
49. Bongiovanni A, Liverani C, Recine F, Mercatali L, Severi S, Ibrahim T. Comment on the Paper by Lemelin et al. Entitled "Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study". *Neuroendocrinology.* 2020;110(7-8):721-722 IF= 5.135
50. Recine F, Bongiovanni A, Foca F, et al. BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study). *J Clin Med.* 2019;8(11):1894. Published 2019 Nov 6. doi:10.3390/jcm8111894 IF 4.964
51. Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management- An Updated Review. *Front Oncol.* 2020 May 27;10:831. IF 5.738
52. Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C,

Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D; ItaNet. Nonconventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor. *J Clin Endocrinol Metab.* 2019 Sep 23. IF= 6.134

53. Liverani C, De Vita A, Minardi S, Kang Y, Mercatali L, Amadori D, Bongiovanni A, La Manna F, Ibrahim T, Tasciotti E. A biomimetic 3D model of hypoxia-driven cancer progression. *Sci Rep.* 2019 Aug 22;9(1):12263. IF=4.997

54. Bongiovanni A, Recine F, Fausti V, Rossi B, Mercatali L, Liverani C, De Vita A, Gurrieri L, De Bonis S, Miserocchi G, Spadazzi C, Calpona S, Riva N, Cocchi C, Ibrahim T. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: an evidence- based review. *Int J Clin Pract.* 2019 Aug 13:e13404. IF= 3.149

55. Spadazzi C, Recine F, Mercatali L, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Fausti V, Ibrahim T mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. *J Bone Oncol.* 2019 Feb 27;16:100227. doi: 10.1016/j.jbo.2019.100227. IF 4.491

56. Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T. Ten- year experience of the multidisciplinary Osteoncology Center. *Support Care Cancer.* 2019 Jan 16. IF 3.359

57. Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. *Dis Markers.* 2018 Dec 2;2018:6878409. IF 3.464

58. Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. *Endocr Connect.* 2018 Dec 1. IF 3.221

59. Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T. Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. *Cells.* 2018 Oct 25;7(11). IF 7.666

60. Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D. Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers. *J Vis Exp.* 2018 Jun 11;(136). IF 1.424

61. De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T. Establishment of a Primary Culture of Patientderived Soft Tissue Sarcoma. *J Vis Exp.* 2018 Apr 11;(134). IF 1.424

62. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davi MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018 Aug;155(2):479-489.e7. IF 33.883
63. De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. *Ther Adv Med Oncol*. 2017 Dec;9(12):755-767. IF 5.485
64. Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G. Investigation of receptor radionuclide therapy with ¹⁷⁷LuDOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. *Eur J Nucl Med Mol Imaging*. 2018 Jun;45(6):923-930. IF= 10.057
65. Rinzivillo M, Fazio N, Pusceddu S, Spallanzani A, Ibrahim T, Campana D, Marconcini R, Partelli S, Badalamenti G, Brizzi MP, Catena L, Schinzari G, Carnaghi C, Berardi R, Faggiano A, Antonuzzo L, Spada F, Gritti S, Femia D, Gelsomino F, Bongiovanni A, Ricci S, Brighi N, Falconi M, Delle Fave G, Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. *Pancreatology*. 2018 Mar;18(2):198-203. IF 3.977
66. De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. *Int J Mol Sci*. 2017 Dec 8;18(12). IF 3.642
67. Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T. Primary leiomyosarcoma of the bone: a case report and a review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(45):e8545. IF 1.552
68. Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by ¹⁸F-fluorocholine PET/CT and its comparison with ⁶⁸Ga-gallium-DOTATOC PET/CT: Case report and review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(46):e8567. IF 1.552

69. Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med.* 2017 Nov 7;15(1):229. IF 8.448
70. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. *J Vis Exp.* 2017 Sep 13;(127) IF 1.232
71. Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int J Mol Sci.* 2017 Jul 29;18(8). IF 6.208
72. Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, De Braud F, Falconi M, Cascinu S. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. *Cancer Med.* 2017 Jul;6(7):1493-1499. IF= 4.711
73. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther.* 2017 Feb 23;10:1155-1164. IF= 4.345
74. Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. *Onco Targets Ther.* 2017 Jan 27;10:551-557. IF= 4.345
75. Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L. Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. *Oncotarget.* 2017 Feb 21;8(8):13142-13156. IF= 5.168
76. Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT. *Clin Lung Cancer.* 2017 Jul;18(4):415-420. IF= 4.840
77. De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T. Activity of Eribulin in a Primary

Culture of Well- Differentiated/Dedifferentiated Adipocytic Sarcoma. *Molecules*. 2016 Dec 3;21(12). IF 4.927

78. Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, SnaarJagalska E, Ibrahim T. *Biol Open*. 2017 Feb 15;6(2):133-140. IF= 2.643

79. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. *Int J Mol Sci*. 2016 Nov 1;17(11) IF 6.208

80. Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE. *Eur J Nucl Med Mol Imaging*. 2017 Mar;44(3):490-499 IF= 10.057

81. De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. *Onco Targets Ther*. 2016 Oct 11;9:6233- 6246. IF= 4.345

82. Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Ceconetto L, Amadori D, Mercatali L. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016 Oct;12(4):2970-2975 IF

=3.111

83. Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). *Support Care Cancer*. 2017 Jan;25(1):111-117. IF: 3.359

84. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. *Int J Mol Sci*. 2016 Aug 22;17(8). IF 6.208

85. Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. *BMC Cancer*. 2015 Dec 22;15:998. IF 4.638

86. Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T. First-line chemotherapy in patients with metastatic

gastroenteropancreatic neuroendocrine carcinoma. *Onco Targets Ther.* 2015 Dec 3;8:3613-9. IF= 4.345

87. Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. *Eur J Nucl Med Mol Imaging.* 2016 Jun;43(6):1040-6. IF=10.057

88. Genestreti G, Tiseo M, Kenmotsu H, Kazushige W, Di Battista M, Cavallo G, Carloni F, Bongiovanni A, Burgio MA, Casanova C, Metro G, Scarpi E, Korkmaz T, Selcuk S, Roopa K, Califano R. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. *Clin Lung Cancer.* 2015 Nov;16(6):e223-8. IF= 4.840

89. Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol.* 2014 Dec;10(15):2423-7. IF= 2.660

90. Genestreti G, Grossi F, Genova C, Burgio MA, Bongiovanni A, Gavelli G, Bartolotti M, Di Battista M, Cavallo G, Brandes AA. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. *Future Oncol.* 2014 Oct;10(13):2081-96. IF= 3.674

91. Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori E, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther.* 2014 Oct 20;7:1919-26 .IF= 4.345

92. Genestreti G, Bongiovanni A, Burgio MA, Burgio SL, Musto A, Rossi A, Monti M, Scarpi E, Ulivi P, Bravaccini S, Dubini A, Matteucci F, Gavelli G. 111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significance. *Nucl Med Commun.* 2015 Feb;36(2):135-42. IF= 1.698

93. Ricci M, Amadori E, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol.* 2014 Aug;10(10):1735-9. IF= 2.660

94. Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade

impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone*. 2014 Sep;66:214-22. IF = 4.626

95. Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C, Accardo A, Verna R, Candore G, Caruso C, Lio D, Palmeri S. Cytokine gene polymorphisms and breast cancer susceptibility. *Ann N Y Acad Sci*. 2006 Nov;1089:104-9. IF= 6.499

96. Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Di Noto L, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D, Palmeri S. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. *Ann N Y Acad Sci*. 2006 Nov;1089:98-103. IF= 6.499

Awards and Honours

- 2017: Oral presentation award, ISO Congress (Padua).
- 2020: Performance Award for best competitive grant project (IRST "Dino Amadori").
- 2021: Winner, access to 22nd EORTC-ESMO-AACR Workshop on Methods in Clinical Cancer Research, Sint-Michielsgestel.

Organisational and Institutional Roles

- Contributor to national and regional oncology guidelines (AIOM, Emilia Romagna PDTA).
- Organiser of multidisciplinary tumour boards (Neuroendocrine Tumours, 2018–2022).
- EURACAN representative for IRST until 2023, responsible for European Reference Network accreditation and data reporting.
- Member of the Phase I Unit, IRST Meldola (2018–2021, 2021–2023).

Languages and IT Skills

- Languages: Fluent in English (spoken and written), basic knowledge of French.
- IT skills: Excellent command of Microsoft Office, good knowledge of SPSS and bioinformatics databases.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016, I hereby express my consent to process and use my data provided in this CV and application for recruiting purposes